文献速递妇科

在铂耐药复发性卵巢癌单药化疗中加入贝伐珠单抗的成本效果分析:基于AURELIA试验

Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial.
PubMed 文献 · Gynecol Oncol · 2017-03-11

基于AURELIA随机III期试验构建决策树模型,评估在铂耐药复发性卵巢癌单药化疗中加入贝伐珠单抗的成本效果。每获得一个QALY的增量成本效果比为410,455美元,每挽救一个无进展生命年的增量成本效果比为217,080美元;在50,000美元/QALY和100,000美元/QALY的支付意愿阈值下均不具成本效果。

要点

  • 贝伐珠单抗联合单药化疗每获得一个QALY的增量成本效果比为410,455美元。
  • 每挽救一个无进展生命年的增量成本效果比为217,080美元。
  • 在50,000美元/QALY和100,000美元/QALY支付意愿阈值下均不具成本效果。

核心结论

  • 尽管贝伐珠单抗联合单药化疗在铂耐药复发性卵巢癌中改善了QALY和无进展生存,但不具成本效果。
  • 为该患者群体开具化疗时,应考虑治疗相关的获益、风险和成本。

研究设计与样本

  • 基于AURELIA随机III期试验的两个治疗组构建决策树模型。
  • 模型评估在单药化疗(CT)基础上加入贝伐珠单抗(B)的成本效果,时间跨度为15个月。
  • 模型输入参数取自已发表文献和公开来源。

主要发现

  • B+CT组的增量成本效果比为每获得一个QALY 410,455美元。
  • B+CT组的增量成本效果比为每挽救一个无进展生命年217,080美元。
  • 在50,000美元/QALY的支付意愿阈值下,B+CT对该患者群体不具成本效果。
  • 即使在100,000美元/QALY的支付意愿阈值下,B+CT仍不具成本效果。
  • 上述结果经敏感性分析稳健。

关键数值与推荐

  • 增量成本效果比(ICER)为每获得一个QALY 410,455美元。
  • 增量成本效果比为每挽救一个无进展生命年(PF-LYS)217,080美元。
  • 支付意愿阈值50,000美元/QALY下不具成本效果。
  • 支付意愿阈值100,000美元/QALY下不具成本效果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: AURELIA, a randomized phase III trial of adding bevacizumab (B) to single agent chemotherapy (CT) for the treatment of platinum-resistant recurrent ovarian cancer, demonstrated improved progression free survival (PFS) in the B+CT arm compared to CT alone. We aimed to evaluate the cost effectiveness of adding B to CT in the treatment of platinum-resistant recurrent ovarian cancer. METHODS: A decision tree model was constructed to evaluate the cost effectiveness of adding bevacizumab (B) to single agent chemotherapy (CT) based on the arms of the AURELIA trial. Costs, quality-adjusted life years (QALYs), and progression free survival (PFS) were modeled over fifteen months. Model inputs were extracted from published literature and public sources. Incremental cost effectiveness ratios (ICERs) per QALY gained and ICERs per progression free life year saved (PF-LYS) were calculated. One-way sensitivity analyses were performed to evaluate the robustness of results. RESULTS: The ICER associated with B+CT is $410,455 per QALY gained and $217,080 per PF-LYS. At a willingness to pay (WTP) threshold of $50,000/QALY, adding B to single agent CT is not cost effective for this patient population. Even at a WTP threshold of $100,000/QALY, B+CT is not cost effective. These findings are robust to sensitivity analyses. CONCLUSIONS: Despite gains in QALY and PFS, the addition of B to single agent CT for treatment of platinum-resistant recurrent ovarian cancer is not cost effective. Benefits, risks, and costs associated with treatment should be taken into consideration when prescribing chemotherapy for this patient population.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Wysham WZ, Schaffer EM, Coles T, et al. Adding bevacizumab to single agent chemotherapy for the treatment of platinum-resistant recurrent ovarian cancer: A cost effectiveness analysis of the AURELIA trial. Gynecol Oncol. 2017. PMID: 28291545. doi:10.1016/j.ygyno.2017.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。